Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Aura

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    263 result(s) found for: Aura. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-001288-18 Sponsor Protocol Number: 16-API-01 Start Date*: 2019-01-08
    Sponsor Name:CHU de Nice
    Full Title: ASIC channels and migraine disorders - Proof of concept study on the efficacy of Amiloride in prophylaxis of Migraine with Aura - APAM study
    Medical condition: Migraine with aura
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-010721-39 Sponsor Protocol Number: NXN-188-202 Start Date*: 2009-04-27
    Sponsor Name:Peer Tfelt-Hansen
    Full Title: A phase 2a Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks with Aura
    Medical condition: MIgraine with aura
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027607 Migraine with aura LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002470-27 Sponsor Protocol Number: 3101-312-002 Start Date*: 2021-05-12
    Sponsor Name:Allergan Limited
    Full Title: A PHASE 3, MULTICENTER, OPEN-LABEL 52-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH CHRONIC OR EPISODI...
    Medical condition: Chronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    21.1 10029205 - Nervous system disorders 10066636 Chronic migraine LLT
    22.0 10029205 - Nervous system disorders 10082019 Episodic migraine LLT
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) SE (Completed) HU (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005689-40 Sponsor Protocol Number: COL-MIG-302 Start Date*: 2016-10-18
    Sponsor Name:CoLucid Pharmaceuticals, Inc.
    Full Title: A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A randomized, double-blind, placebo-controlled parallel group study (SPARTAN)
    Medical condition: acute migraine
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10066635 Acute migraine LLT
    19.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    19.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    19.0 10029205 - Nervous system disorders 10027599 Migraine PT
    19.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005239-22 Sponsor Protocol Number: BHV3000-404 Start Date*: 2022-06-20
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention with Multiple Dosing Regimens
    Medical condition: Acute Migraine (with or without aura)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    20.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Completed) FR (Completed) SE (Completed) IT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005246-15 Sponsor Protocol Number: BHV3000-315 Start Date*: 2022-08-23
    Sponsor Name:Biohaven Pharmaceuticals Holding Company Limited
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 years of age
    Medical condition: Acute Migraine (with or without aura)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    20.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005674-37 Sponsor Protocol Number: COL-MIG-305(H8H-CD-LAHL) Start Date*: 2016-11-01
    Sponsor Name:Eli Lilly and Company
    Full Title: An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
    Medical condition: acute migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10066635 Acute migraine LLT
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003761-18 Sponsor Protocol Number: BHV3000-312 Start Date*: 2022-01-20
    Sponsor Name:Biohaven Pharmaceuticals Inc.
    Full Title: Phase 3, multicenter, open-label study to assess the long-term safety and tolerability of rimegepant for the acute treatment of migraine (with or without aura) in children and adolescents ≥ 6 to < ...
    Medical condition: Acute Migraine (with or without aura)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    21.1 10029205 - Nervous system disorders 10066635 Acute migraine LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-000210-21 Sponsor Protocol Number: TON/02/05-CLIN Start Date*: 2006-03-27
    Sponsor Name:Prof Jes Olesen
    Full Title: A single centre, double-blind, randomised, placebo controlled cross-over study to evaluate the efficacy and tolerability of tonabersat in the prophylaxis of migraine in patients presenting with mig...
    Medical condition: Migraine with aura meeting the diagnostic criteria of the International Classification of Headache Disorders (Edition 2)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003517-35 Sponsor Protocol Number: BHV3000-311 Start Date*: 2021-05-05
    Sponsor Name:Pfizer, Inc.
    Full Title: Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in childr...
    Medical condition: Acute Migraine (with or without aura)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    21.1 10029205 - Nervous system disorders 10066635 Acute migraine LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006207-36 Sponsor Protocol Number: 19122011 Start Date*: 2012-09-27
    Sponsor Name:Proreo Pharma Innovation AG
    Full Title: A multi centre, double blind, randomised, placebo controlled crossover study to evaluate the efficacy and tolerability of picotamide in the prophylaxis of migraine in patients presenting with migra...
    Medical condition: Migraine with aura, ICD-10NA G43.1
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-007336-17 Sponsor Protocol Number: Version1.10 Start Date*: 2009-08-06
    Sponsor Name:Medizinische Universität Wien, Uni. Klinik für Neurologie
    Full Title: Blockade of the greater occipital nerve in frequent migraine and medication-overuse headache - a double-blinded, randomized, controlled trial
    Medical condition: frequent migraine (defined at least 8 attacks per month) and medication-overuse headache
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-011009-18 Sponsor Protocol Number: ALO-FC-001 Start Date*: 2009-04-20
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
    Full Title: Pilot study on the efficacy of IV haloperidol in the treatment of chronic migraine with and without medication overuse
    Medical condition: Chronic migraine with and without medication overuse
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029205 SOC
    9.1 10019231 HLGT
    9.1 10027603 HLT
    9.1 10056236 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000661-16 Sponsor Protocol Number: CGRP2020 Start Date*: 2020-06-18
    Sponsor Name:Rigshospitalet Glostrup
    Full Title: The effect of anti-calcitonin gene-related peptide (CGRP) receptor antibodies on the headache inducing properties of CGRP and cilostazol in migraine patients
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-002654-36 Sponsor Protocol Number: Zomig nasal 5mg/Imigran novum 100mg Start Date*: 2007-10-08
    Sponsor Name:Carl Dahlöf
    Full Title: A randomised prospective open multi-attack study of patient preference and efficacy between zolmitriptan nasal spray 5 mg and sumatriptan RDT 100 mg in the acute treatment of migraine.
    Medical condition: Migraine with and without aura (G 43.0 and G 43.1)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004835-23 Sponsor Protocol Number: TON/01/05-CLIN Start Date*: 2006-01-26
    Sponsor Name:Minster Pharmaceuticals Ltd
    Full Title: Multi-centre, parallel group, double-blind, placebo controlled study of the efficacy and tolerability of TONABERSAT in prophylaxis of migraine headache
    Medical condition: Migraine with or without aura meeting the diagnostic criteria of the International Classification of Headache Disorders (Edition 2).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-001989-15 Sponsor Protocol Number: TV48125-MH-40142 Start Date*: 2020-03-27
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of...
    Medical condition: Migraine and major depressive disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027603 Migraine headaches HLT
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) FR (Completed) FI (Completed) GR (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003223-30 Sponsor Protocol Number: HeMiLa Start Date*: 2017-08-14
    Sponsor Name:University Hospital Tübingen
    Full Title: Prophylactic treatment of hemiplegic migraine with Lamotrigine
    Medical condition: Familiar hemplegic migraine
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006219-28 Sponsor Protocol Number: MRSI Start Date*: 2022-02-24
    Sponsor Name:Medical University Innsbruck
    Full Title: MR-Spectroscopy: Investigating neurochemical changes in brain metabolism in migraineurs before and after CGRPAntibody treatment – a randomized, controlled, open-label trial
    Medical condition: Episodic migraine
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016375-30 Sponsor Protocol Number: MK-0462-086 Start Date*: 2010-02-16
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Aura
    Medical condition: Long term treatment of acute migraine, with or without aura, in children and adolescents, ages 12 to 17 years.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10066635 Acute migraine LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DE (Completed) BE (Completed) ES (Prematurely Ended) EE (Completed) LV (Prematurely Ended) SE (Completed) FR (Prematurely Ended) PL (Prematurely Ended) DK (Completed) NO (Completed) GB (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 03:07:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA